Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds

Journal of Medicinal Chemistry

Volumn 48, Issue 9, 2005, Pages 3280-3289

  Tamamura, Hirokazu ^a,b   Araki, Takanobu ^a   Ueda, Satoshi ^a   Wang, Zixuan ^c   Oishi, Shinya ^a   Esaka, Ai ^a   Trent, John O ^d   Nakashima, Hideki ^e   Yamamoto, Naoki ^b   Peiper, Stephen C ^c   Otaka, Akira ^a   Fujii, Nobutaka ^a  

^a KYOTO UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d UNIVERSITY OF LOUISVILLE   (United States)

^e ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKENE; AMINO ACID; ARGININE; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CYCLOPEPTIDE; DIPEPTIDE; DISULFIDE; GAMMA AMINO ACID; PENTAPEPTIDE; PEPTIDE LIBRARY; PSEUDOPEPTIDE; TETRAPEPTIDE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL BOND; CHEMICAL MODIFICATION; CYCLIZATION; DRUG ACTIVITY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SYNTHESIS; PHARMACOPHORE; PROTEIN CONFORMATION;

ALKENES; ANIMALS; ARGININE; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; CRICETULUS; MODELS, MOLECULAR; MOLECULAR MIMICRY; OLIGOPEPTIDES; PEPTIDES, CYCLIC; RADIOLIGAND ASSAY; RECEPTORS, CXCR4; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFIDES;

EID: 20944452022     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050009h     Document Type: Article

References (56)

1. Nagasawa, T.; Kikutani, H.; Kishimoto, T. Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 2305-2309.
2. Bleul, C. C.; Farzan, M.; Choe, H.; Parolin, C.; Clark-Lewis, I.; Sodroski, J.; Springer, T. A. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996, 382, 829-833.
3. Oberlin, E.; Amara, A.; Bachelerie, F.; Bessia, C.; Virelizier, J.-L.; Arenzana-Seisdedos, F.; Schwartz, O.; Heard, J.-M.; Clark-Lewis, I.; Legler, D. F.; Loetscher, M.; Baggiolini, M.; Moser, B. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996, 382, 833-835.
4. Tashiro, K.; Tada, H.; Heilker, R.; Shirozu, M.; Nakano, T.; Honjo, T. Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. Science 1993, 261, 600-603.
5. Feng, Y.; Broder, C. C.; Kennedy, P. E.; Berger, E. A. HIV-1 entry co-factor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272, 872-877.
6. Müller, A.; Homey, B.; Soto, H.; Ge, N.; Catron, D.; Buchanan, M. E.; McClanahan, T.; Murphy, E.; Yuan, W.; Wagner, S. N.; Barrera, J. L.; Mohar, A.; Verastegui, E.; Zlotnik, A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410, 50-56.
7. Koshiba, T.; Hosotani, R.; Miyamoto, Y.; Ida, J.; Tsuji, S.; Nakamura, S.; Kawaguchi, M.; Kobayashi, H.; Doi, R.; Hori, T.; Fujii, N.; Imamura, M. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin. Cancer Res. 2000, 6, 3530-3535.
8. Mori, T.; Doi, R.; Koizumi, K.; Toyoda, E.; Tulachan, S. S.; Ito, D.; Kami, K.; Masui, T.; Fujimoto, K.; Tamamura, H.; Hiramatsu, K.; Fujii, N.; Imamura, M. CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol. Cancer Ther. 2004, 3, 29-37.
9. Robledo, M. M.; Bartolome, R. A.; Longo, N.; Miguel Rodriguez-Frade, J.; Mellado, M.; Longo, I.; van Muijen, G. N. P.; Sanchez-Mateos, P.; Teixido, J. Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. J. Biol. Chem. 2001, 276, 45098-45105.
10. Taichman, R. S.; Cooper, C.; Keller, E. T.; Pienta, K. J.; Taichman, N. S.; McCauley, L. K. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer matastasis to bone. Cancer Res. 2002, 62, 1832-1837.
11. Schrader, A. J.; Lechner, O.; Templin, M.; Dittmar, K. E. J.; Machtens, S.; Mengel, M.; Probst-Kepper, M.; Franzke, A.; Wollensak, T.; Gatzlaff, P.; Atzpodien, J.; Buer, J.; Lauber, J. CXCR4/CXCL12 expression and signalling in kidney cancer. Br. J. Cancer 2002, 86, 1250-1256.
12. Geminder, H.; Sagi-Assif, O.; Goldberg, L.; Meshel, T.; Rechavi, G.; Witz, I. P.; Ben-Baruch, A. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J. Immunol. 2001, 167, 4747-4757.
13. Bertolini, F.; Dell'Agnola, C.; Mancuso, P.; Rabascio, C.; Burlini, A.; Monestiroli, S.; Gobbi, A.; Pruneri, G.; Martinelli, G. CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res. 2002, 62, 3106-3112.
14. Kijima, T.; Maulik, G.; Ma, P. C.; Tibaldi, E. V.; Turner, R. E.; Rollins, B.; Sattler, M.; Johnson, B. E.; Salgia, R. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res. 2002, 62, 6304-6311.
15. Scotton, C. J.; Wilson, J. L.; Milliken, D.; Stamp, G.; Balkwill, F. R. Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res. 2001, 61, 4961-4965.
16. Scotton, C. J.; Wilson, J. L.; Scott, K.; Stamp, G.; Wilbanks, G. D.; Fricker, S.; Bridger, G.; Balkwill, F. R. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res. 2002, 62, 5930-5938.
17. Sanz-Rodriguez, F.; Hidalgo, A.; Teixido, J. Chemokine stromal cell-derived factor-1α modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood 2001, 97, 346-351.
18. Tsukada, N.; Burger, J. A.; Zvaifler, N. J.; Kipps, T. J. Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. Blood 2002, 99, 1030-1037.
19. Juarez, J.; Bradstock, K. F.; Gottlieb, D. J.; Bendall, L. J. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia 2003, 17, 1294-1300.
20. Rubin, J. B.; Kung, A. L.; Klein, R. S.; Chan, J. A.; Sun, Y.-P.; Schmidt, K.; Kieran, M. W.; Luster, A. D.; Segal, R. A. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 13513-13518.
21. + T cell accumulation in rheumatoid arthritis synovium. J. Immunol. 2000, 165, 6590-6598.
22. Tamamura, H.; Xu, Y.; Hattori, T.; Zhang, X.; Arakaki, R.; Kanbara, K.; Omagari, A.; Otaka, A.; Ibuka, T.; Yamamoto, N.; Nakashima, H.; Fujii, N. A low molecular weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem. Biophys. Res. Commun. 1998, 253, 877-882.
23. Tamamura, H.; Hori, A.; Kanzaki, N.; Hiramatsu, K.; Mizumoto, M.; Nakashima, H.; Yamamoto, N.; Otaka, A.; Fujii, N. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett. 2003, 550, 79-83.
24. Tamamura, H.; Fujisawa, M.; Hiramatsu, K.; Mizumoto, M.; Nakashima, H.; Yamamoto, N.; Otaka, A.; Fujii, N. Identification of a CXCR4 antagonist, a T140 analog, as an anti-rheumatoid arthritis agent. FEBS Lett. 2004, 569, 99-104.
25. Tamamura, H.; Omagari, A.; Oishi, S.; Kanamoto, T.; Yamamoto, N.; Peiper, S. C.; Nakashima, H.; Otaka, A.; Fujii, N. Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes. Bioorg. Med. Chem. Lett. 2000, 10, 2633-2637.
26. Fujii, N.; Oishi, S.; Hiramatsu, K.; Araki, T.; Ueda, S.; Tamamura, H.; Otaka, A.; Kusano, S.; Terakubo, S.; Nakashima, H.; Broach, J. A.; Trent, J. O.; Wang, Z.; Peiper, S. C. Molecular-size reduction of a potent CXCR4-chemokine antagonist using orthogonal combination of conformation- and sequence-based libraries. Angew. Chem., Int. Ed. 2003, 42, 3251-3253.
27. Fukami, T.; Nagase, T.; Fujita, K.; Hayama, T.; Niiyama, K.; Mase, T.; Nakajima, S.; Fukuroda, T.; Saeki, T.; Nishikibe, M.; Ihara, M.; Yano, M.; Ishikawa, K. Structure-activity relationships of cyclic pentapeptide endothelin A receptor antagonists. J. Med. Chem. 1995, 38, 4309-4324.
28. Haubner, R.; Gratias, R.; Diefenbach, B.; Goodman, S. L.; Jonczyk, A.; Kessler, H. Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin αVβ3 antagonists. J. Am. Chem. Soc. 1996, 118, 7461-7472.
29. Spatola, A. F.; Crozet, Y.; deWit, D.; Yanagisawa, M. Rediscovering an endothelin antagonist (BQ-123): A self-deconvoluting cyclic pentapeptide library. J. Med. Chem. 1996, 39, 3842-3846.
30. Wermuth, J.; Goodman, S. L.; Jonczyk, A.; Kessler, H. Stereoisomerism and biological activity of the selective and superactive αVβ3 integrin inhibitor cyclo(-RGDfV-) and its retro-inverso peptide. J. Am. Chem. Soc. 1997, 119, 1328-1335.
31. Haubner, R.; Finsinger, D.; Kessler, H. Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the αVβ3 integrin for a new cancer therapy. Angew. Chem., Int. Ed. Engl. 1997, 36, 1374-1389.
32. Porcelli, M.; Casu, M.; Lai, A.; Saba, G.; Pinori, M.; Cappelletti, S.; Mascagni, P. Cyclic pentapeptides of chiral sequence DLDDL as scaffold for antagonism of G-protein coupled receptors: Synthesis, activity and conformational analysis by NMR and molecular dynamics of ITF 1565 a substance P inhibitor. Biopolymers 1999, 50, 211-219.
33. Oishi, S.; Kamano, T.; Niida, A.; Odagaki, Y.; Hamanaka, N.; Yamamoto, M.; Ajito, K.; Tamamura, H.; Otaka, A.; Fujii, N. Diastereoselective synthesis of new ψ[[(E)-CH=CMe]- and ψ-[[(Z)-CH=CMe]-type alkene dipeptide isosteres by organocopper reagents and application to conformationally restricted cyclic RGD peptidomimetics. J. Org. Chem. 2002, 67, 6162-6173.
34. Nikiforovich, G. V.; Kover, K. E.; Zhang, W.-J.; Marshall, G. R. Cyclopentapeptides as flexible conformational templates. J. Am. Chem. Soc. 2000, 122, 3262-3273.
35. Tamamura, H.; Hiramatsu, K.; Ueda, S.; Wang, Z.; Kusano, S.; Terakubo, S.; Trent, J. O.; Peiper, S. C.; Yamamoto, N.; Nakashima, H.; Otaka, A.; Fujii, N. Stereoselective synthesis of [L-Arg-L/D-3-(2-naphthyl)alanine]-type (E)-alkene dipeptide isosteres and its application to the synthesis and biological evaluation of pseudopeptide analogues of the CXCR4 antagonist FC131. J. Med. Chem. 2005, 48, 380-391.
36. Abdel-Magid, A. F.; Maryanoff, C. A.; Carson, K. G. Reductive animation of aldehydes and ketones by using sodium triacetoxyborohydride. Tetrahedron Lett. 1990, 31, 5595-5598.
37. Fukuyama, T.; Jow, C.-K.; Cheung, M. 2- and 4-Nitrobenzene-sulfonamides: exceptionally versatile means for preparation of secondary amines and protection of amines. Tetrahedron Lett. 1995, 36, 6373-6374.
38. Myers, A. G.; Gleason, J. L.; Yoon, T.; Kung, D. W. Highly practical methodology for the synthesis of D- and L-R-amino acids, N-protected R-amino acids, and N-methyl-R-amino acids. J. Am. Chem. Soc. 1997, 119, 656-673.
39. Travins, J. M.; Etzkorn, F. A. Facile synthesis of D-amino acids from an L-serine-derived aziridine. Tetrahedron Lett. 1998, 39, 9389-9392.
40. Biagini, S. C. G.; Gibson, S. E.; Keen, S. P. Cross-metathesis of unsaturated α-amino acid derivatives. J. Chem. Soc., Perkin. Trans. 1 1998, 2485-2499.
41. Oppolzer, W.; Lienard, P. Non-destructive cleavage of N-acyl-sultams under neutral conditions: preparation of enantiomerically pure, Fmoc-protected α-amino acids. Helv. Chim. Acta 1992, 75, 2572-2582.
42. Douat, C.; Heitz, A.; Martinez, J.; Fehrentz, J.-A. Stereoselective synthesis of allyl- and homoallylglycines. Tetrahedron Lett. 2001, 42, 3319-3321.
43. Scholl, M.; Ding, S.; Lee, C. W.; Grubbs, R. H. Synthesis and activity of a new generation of ruthenium-based olefin metathesis catalysts coordinated with 1,3-dimesityl-4,5-dihydroimidazol-2-ylidene ligands. Org. Lett. 1999, 1, 953-956.
44. Tamaki, M.; Han, G.; Hruby, V. J. Practical and efficient synthesis of orthogonally protected constrained 4-guanidinoprolines. J. Org. Chem. 2001, 66, 1038-1042.
45. Tamamura, H.; Sugioka, M.; Odagaki, Y.; Omagari, A.; Kan, Y.; Oishi, S.; Nakashima, H.; Yamamoto, N.; Peiper, S. C.; Hamanaka, N.; Otaka, A.; Fujii, N. Conformational study of a highly specific CXCR4 inhibitor, T140, disclosing the close proximity of its intrinsic pharmacophores associated with strong anti-HIV activity. Bioorg. Med. Chem. Lett. 2001, 11, 359-362 and 2409.
46. Intramolecular hydrogen bonds were not observed in the calculated structures of these cyclic pentapeptides. Thus, these peptides do not seem to exist in a characteristic turn conformation such as a βII'γ turn as reported in several papers concerning normal cyclic pentapeptides, see Weisshoff, H.; Prasang, C.; Henklein, P.; Frommel, C.; Zschunke, A.; Mugge, C. Mimicry of βII'-turns of proteins in cyclic pentapeptides with one and without D-amino acids. Eur. J. Biochem. 1999, 259, 776-788.
47. Murakami, T.; Nakajima, T.; Koyanagi, Y.; Tachibana, K.; Fujii, N.; Tamamura, H.; Yoshida, N.; Waki, M.; Matsumoto, A.; Yoshie, O.; Kishimoto, T.; Yamamoto, N.; Nagasawa, T. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J. Exp. Med. 1997, 186, 1389-1393.
48. Schols, D.; Struyf, S.; Van Damme, J.; Este, J. A.; Henson, G.; De Clercq, E. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J. Exp. Med. 1997, 186, 1383-1388.
49. Donzella, G. A.; Schols, D.; Lin, S. W.; Este J. A.; Nagashima, K. A.; Maddon, P. J.; Allaway, G. P.; Sakmar, T. P.; Henson, G.; De Clercq, E.; Moore, J. P. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med. 1998, 4, 72-77.
50. Doranz, B. J.; Grovit-Ferbas, K.; Sharron, M. P.; Mao, S.-H.; Bidwell Goetz, M.; Daar, E. S.; Doms, R. W.; O'Brien, W. A. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J. Exp. Med. 1997, 186, 1395-1400.
51. Howard, O. M. Z.; Oppenheim, J. J.; Hollingshead, M. G.; Covey, J. M.; Bigelow, J.; McCormack, J. J.; Buckheit, Jr., R. W.; Clanton, D. J.; Turpin, J. A.; Rice, W. G. Inhibition of in vitro and in vivo HIV replication by a distamycin analogue that interferes with chemokine receptor function: a candidate for chemotherapeutic and microbicidal application. J. Med. Chem. 1998, 41, 2184-2193.
52. Fujii, N.; Nakashima, H.; Tamamura, H. The Therapeutic Potential of CXCR4 Antagonists in the Treatment of HIV. Expert Opin. Investig. Drugs 2003, 12, 185-195.
53. Tamamura, H.; Fujii, N. Two Orthogonal Approaches to Overcome Multi-Drug Resistant HIV-1s: Development of Protease Inhibitors and Entry Inhibitors Based on CXCR4 Antagonists. Curr. Drug Targets-Infect. Disord. 2004, 4, 103-110.
54. Navenot, J. M.; Wang , Z. X.; Trent, J. O.; Murray, J. L.; Hu, Q. X.; DeLeeuw, L.; Moore, P. S.; Chang, Y.; Peiper, S. C. Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: Differences in primary structural requirements for RANTES, MIP-1α, and vMIP-II binding. J. Mol. Biol. 2001, 313, 1181-1193.
55. Miyamoto, K.; Nakagawa, T.; Kuroda, Y. Solution structure of the cytoplasmic linker between domain III-S6 and domain IV-S1 (III-IV linker) of the rat brain sodium channel in SDS micelles. Biopolymers 2001, 59, 380-393.
56. Ludvigsen, S.; Andersen, K. V.; Poulsen, F. M. Accurate measurements of coupling-constants from 2-dimensional nuclear-magnetic-resonance spectra of proteins and determination of φ-angles J. Mol. Biol. 1991, 217, 731-736.